185 related articles for article (PubMed ID: 12570122)
1. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Torres A; Muir JF; Corris P; Kubin R; Duprat-Lomon I; Sagnier PP; Höffken G
Eur Respir J; 2003 Jan; 21(1):135-43. PubMed ID: 12570122
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
4. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
5. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
[TBL] [Abstract][Full Text] [Related]
6. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Lamping DL; Schroter S; Marquis P; Marrel A; Duprat-Lomon I; Sagnier PP
Chest; 2002 Sep; 122(3):920-9. PubMed ID: 12226033
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
8. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
10. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
Int J Antimicrob Agents; 2000 Jul; 15(2):149-52. PubMed ID: 10854812
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
12. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin for community-acquired pneumonia.
Rijnders BJ
Antimicrob Agents Chemother; 2003 Jan; 47(1):444; author reply 444-5. PubMed ID: 12499236
[No Abstract] [Full Text] [Related]
14. [Role of moxifloxacin in the treatment of community-acquired pneumonia].
Máthé A; Tóth K; Kovács G
Orv Hetil; 2004 Oct; 145(44):2227-30. PubMed ID: 15626167
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
[TBL] [Abstract][Full Text] [Related]
17. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
Wilson R; Kubin R; Ballin I; Deppermann KM; Bassaris HP; Leophonte P; Schreurs AJ; Torres A; Sommerauer B
J Antimicrob Chemother; 1999 Oct; 44(4):501-13. PubMed ID: 10588312
[TBL] [Abstract][Full Text] [Related]
18. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
